TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1248096

Group type: EXPERIMENTAL
Intervention: Automatic device for metered dose release
Number of subjects: 0
Study: 29055655

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (usual education by diabetes educators)
Number of subjects: 200
Study: 26903254

Group type: EXPERIMENTAL
Intervention: Active ABM intervention (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo ABM training (n = 22)
Number of subjects: 45
Study: 23963355

Group type: EXPERIMENTAL
Intervention: BGG492 (250 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22515794

Group type: EXPERIMENTAL
Intervention: Auricular acupressure intervention (AAP) in addition to standard care (SC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Auricular acupressure using sham auricular points (SAP) in addition to standard care (SC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 10
Study: 20104178

Group type: EXPERIMENTAL
Intervention: Slow repetition speed (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moderate repetition speed (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fast repetition speed (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 30 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 60 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 90 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 120 seconds recovery period (3 x 10 repetitions at 75% resistance maximum)
Number of subjects: 17
Study: 17469682

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions in Alzheimer's disease (AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 16393321

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus fermentum PCC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 12150648

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 10497008

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV), d4T, or NFV + d4T for 24 weeks, followed by triple therapy (NFV + reverse transcriptase inhibitors) for an additional 24 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV), d4T, or NFV + d4T
Number of subjects: 23
Study: 8949803

Group type: EXPERIMENTAL
Intervention: Thoracic impedance (TTI) measurements
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inductance band (IB) signals
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transient respiratory disturbance
Number of subjects: 10
Study: 1918842

Group type: EXPERIMENTAL
Intervention: Sucralfate, 2 g b.i.d.
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sucralfate, 2 g b.i.d. (in smokers)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily (in smokers)
Number of subjects: 165
Study: 6123808

Group type: EXPERIMENTAL
Intervention: Terlipressin ('Glypressin') 2 mg every 6 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vasopressin 0.4 units/min IV infusion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Terlipressin ('Glypressin')
Number of subjects: 19
Study: 31626157

Group type: EXPERIMENTAL
Intervention: Terahertz-modulated infrared radiotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (disease-modifying anti-rheumatic drugs and therapeutic exercises)
Number of subjects: 92
Study: 28947723

Group type: EXPERIMENTAL
Intervention: 20 mg rivaroxaban
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban
Number of subjects: 3365

Group type: COMPARATOR
Intervention: 100 mg aspirin (ASA)
Number of subjects: 3365

Group type: EXPERIMENTAL
Intervention: All treatment groups (20 mg rivaroxaban, 10 mg rivaroxaban, 100 mg ASA)
Number of subjects: 3365
Study: 24912653

Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion of fresh-frozen plasma (FFP) at a dosage of 12 mL/kg
Number of subjects: 81

Group type: COMPARATOR
Intervention: No prophylactic transfusion of fresh-frozen plasma (FFP)
Number of subjects: 81
Study: 25141526

Group type: EXPERIMENTAL
Intervention: LF‐rTMS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study: 22747953

Group type: EXPERIMENTAL
Intervention: First-line and second-line anti-tuberculosis drugs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Streptomycin (SM) and Ofloxacin (OFX)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Isoniazid and SM
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ethionamide, Streptomycin (SM), and Ofloxacin (OFX)
Number of subjects: 5
Study: 21163116

Group type: EXPERIMENTAL
Intervention: Ligustrazine plus chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 60
Study: 18269072

Group type: EXPERIMENTAL
Intervention: Levobupivicaine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 27
Study: 16248392

Group type: EXPERIMENTAL
Intervention: Tc-99m DTPA clearance rate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Spirometric parameters (VC, FVC, FEV1/FVC, FEF 25-75)
Number of subjects: 19

Group type: COMPARATOR
Intervention: DLCO, DLCO/VA, T1/2 values of Tc-99m DTPA clearance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: DLCO/VA and T1/2 values of Tc-99m DTPA clearance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Thyroid hormone levels
Number of subjects: 19
Study: 12390160

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Timolol 0.25%
Number of subjects: 64
Study: 10445198

Group type: EXPERIMENTAL
Intervention: Acrylic IOL (Alcon AcrySof)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hydrogel IOL (Bausch & Lomb Hydroview)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Methyl methacrylate/hydroxyethyl methacrylate IOL (Mentor MemoryLens)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Foldable silicone IOL (Pharmacia 920)
Number of subjects: 120
Study: 7495922

Group type: EXPERIMENTAL
Intervention: Haloperidol maintenance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo replacement
Number of subjects: 30
Study: 2307735

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 24
Study: 7138720

Group type: EXPERIMENTAL
Intervention: i.m. morphine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: high-level extradural morphine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: low-level extradural morphine
Number of subjects: 56
Study: 30119941

Group type: EXPERIMENTAL
Intervention: 1 mg intravenous hydromorphone
Number of subjects: 220

Group type: COMPARATOR
Intervention: 1 g intravenous acetaminophen
Number of subjects: 220
Study: 28943039

Group type: EXPERIMENTAL
Intervention: Patient-specific guides (PSG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional instrumentation (control)
Number of subjects: 50
Study: 25438954

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single‐site cholecystectomy (LSSC)
Number of subjects: 40
Study: 25693331

Group type: EXPERIMENTAL
Intervention: Lower thoracic epidural analgesia (T group)
Number of subjects: 50
Study: 18198642

Group type: COMPARATOR
Intervention: Western medicine (WM) - non-steroid anti-inflammatory agents and slow acting medicine
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) - basic remedy and syndrome differentiating medication
Number of subjects: 397

Group type: COMPARATOR
Intervention: Comparison between CM and WM
Number of subjects: 397
Study: 15473621

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg mL(‐1) 30 mL with epinephrine 5 microg mL(‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline 30 mL with epinephrine 5 microg mL(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Levobupivacaine and Normal saline)
Number of subjects: 0
Study: 11090162

Group type: EXPERIMENTAL
Intervention: Renal transplant patients
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study: 9212474

Group type: EXPERIMENTAL
Intervention: Spinal needles of gauge 26
Number of subjects: 584

Group type: COMPARATOR
Intervention: Spinal needles of gauge 24 and 25
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: All females (including C/S)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Non-obstetric females
Number of subjects: 584

Group type: COMPARATOR
Intervention: Males
Number of subjects: 584
Study: 8451781

Group type: EXPERIMENTAL
Intervention: Gentamicin loading dose of 3 mg/kg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Gentamicin loading dose of 4 mg/kg for younger patients (<= 34 weeks gestational age)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Mean initial dose delivered was 2.41 mg/kg
Number of subjects: 166
Study: 3766683

Group type: EXPERIMENTAL
Intervention: Ballistic extension
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resisted extension
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resisted grasp
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 31928690

Group type: EXPERIMENTAL
Intervention: Alpelisib in combination with fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pan-PI3K inhibitors
Number of subjects: 0
Study: 28972411

Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory (DHI) assessment
Number of subjects: 65
Study: 26328497

Group type: EXPERIMENTAL
Intervention: Hydrophilic rosuvastatin (RSV) for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipophilic pitavastatin (PTV) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both RSV and PTV
Number of subjects: 0
Study: 23485015

Group type: EXPERIMENTAL
Intervention: rTMS targeting Wernicke's and right homologous sites
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: rTMS targeting right homologous site (rW)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: rTMS targeting Wernicke's site (W)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 83
Study: 22044287

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAM) 1.2 g by mouth daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 19825328

Group type: EXPERIMENTAL
Intervention: Film-coated tablets (2 x 12.5 mg diclofenac-K)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sugar-coated tablet (1 x 25 mg diclofenac-K)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 29
Study: 16715914

Group type: EXPERIMENTAL
Intervention: 4% isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.5% isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mask ventilation with isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 40
Study: 15297095

Group type: EXPERIMENTAL
Intervention: Protein-rich liquid formula (Fortimel, 200 ml/day, 20 g protein/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Protein-rich liquid formula (Fortimel, 200 ml/day, 20 g protein/day) + nandrolone decanoate (Deca-Durabol 25 mg i.m./3 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 60
Study: 11465652

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg/day)
Number of subjects: 2504
Study: 9251163

Group type: EXPERIMENTAL
Intervention: Regular or frozen yogurt (palatable food stimuli)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Repeated food presentations
Number of subjects: 36
Study: 8276045

Group type: EXPERIMENTAL
Intervention: Cholic acid (CA) 10 mg.kg‐1 per day for 3 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at the same dose after CA therapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 6
Study: 2880692

Group type: EXPERIMENTAL
Intervention: Oral administration of SMS 201-995 (2 mg) with 75 g of glucose
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control study (not specified)
Number of subjects: 5
Study: 31539635

Group type: EXPERIMENTAL
Intervention: Initial-specimen diversion technique (ISDT)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Standard procedure
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: ISDT
Number of subjects: 756
Study: 29723659

Group type: EXPERIMENTAL
Intervention: Green tea herbal consumed daily for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 27445866

Group type: EXPERIMENTAL
Intervention: GAÏA s‐face program (GAÏA arm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: RECOS program (RECOS arm)
Number of subjects: 40
Study: 24975116

Group type: EXPERIMENTAL
Intervention: Illustrated patient information leaflet (PIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study: 22434324

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (2 mA for 20 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (2 mA for 1 min)
Number of subjects: 9
Study: 20930652

Group type: EXPERIMENTAL
Intervention: Iron gluconate (IG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 105
Study: 18656053

Group type: EXPERIMENTAL
Intervention: Abdominal sacrocolpopexy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 322
Study: 16192518

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12814161

Group type: EXPERIMENTAL
Intervention: IL-17 levels in induced sputum of asthma patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: IL-17 levels in induced sputum of chronic bronchitis patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: IL-17 levels in induced sputum of COPD patients
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison of IL-17 levels in bronchial hyperreactivity group (asthmatics and CB patients)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: IL-17 levels in asthmatic patients with bronchial hyperreactivity
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Correlation of IL-17 levels with PC20
Number of subjects: 56
Study: 10673514

Group type: EXPERIMENTAL
Intervention: FAC plus pretreatment with ethinyl estradiol (EE(2))
Number of subjects: 328

Group type: COMPARATOR
Intervention: FAC chemotherapy alone
Number of subjects: 328
Study: 8857916

Group type: EXPERIMENTAL
Intervention: Cyclic transdermal therapy (17 beta‐estradiol 50 micrograms/d + medroxyprogesterone acetate 10 mg/d for 12 days per cycle)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Continuous oral therapy (17 beta‐estradiol 2 mg/d + norethisterone acetate 1 mg/d for 12 months)
Number of subjects: 120
Study: 1537158

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device
Number of subjects: 22

Group type: COMPARATOR
Intervention: Postoperative splint
Number of subjects: 22
Study: 6380067

Group type: EXPERIMENTAL
Intervention: Isoniazid and ethambutol, thrice weekly for 18 months
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 587
Study: 31797789

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery plus neck dissection
Number of subjects: 0
Study: 29587148

Group type: EXPERIMENTAL
Intervention: Anterolateral approach (ad modum Watson)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Posterior approach (ad modum Moore)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Number of subjects: 28
Study: 27766771

Group type: EXPERIMENTAL
Intervention: Ulinastatin (group U) - 20,000 U/kg/hour for the first hour, then 5,000 U/kg/hour until surgery conclusion
Number of subjects: 108

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ulinastatin (group U)
Number of subjects: 108
Study: 24480945

Group type: EXPERIMENTAL
Intervention: Surgical zipper
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subcuticular Monocryl sutures
Number of subjects: 90
Study: 22901031

Group type: EXPERIMENTAL
Intervention: Learning and mastery course
Number of subjects: 69
Study: 21147743

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antiepileptic treatment
Number of subjects: 0
Study: 17955358

Group type: EXPERIMENTAL
Intervention: L-carnitine 5 g IV bolus followed by 10 g/day IV infusion for 3 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 15681529

Group type: EXPERIMENTAL
Intervention: Prinomastat 15 mg plus gemcitabine-cisplatin chemotherapy
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine-cisplatin chemotherapy
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Prinomastat
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 12473441

Group type: EXPERIMENTAL
Intervention: Midwife care (n = 101)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Doctor care (n = 93)
Number of subjects: 194
Study: 11907945

Group type: EXPERIMENTAL
Intervention: Tibolone (Livial) daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE, Premarin) plus sequential medroxyprogesterone acetate (MPA, Prodafem)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8029587

Group type: EXPERIMENTAL
Intervention: High calorie diet (including Fresubin, a fluid nutrient formula)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 2488701

Group type: EXPERIMENTAL
Intervention: LEYTAS automated screening procedure
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Machine-interaction classification
Number of subjects: 1500
Study: 1093458

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 75 mg meperidine
Number of subjects: 11

Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: meperidine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 11
Study: 30339720

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 43
Study: 28687677

Group type: EXPERIMENTAL
Intervention: HELP intervention (12-session programme)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: HELP intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: HELP intervention and Standard care (control)
Number of subjects: 174
Study: 25847016

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg, two times a day for 3 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ketoprofen 100 mg, two times a day for 3 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (Nimesulide and Ketoprofen)
Number of subjects: 18
Study: 22491708

Group type: EXPERIMENTAL
Intervention: Local infusion analgesia (intermittent bolus intra-articular injection of ropivacaine, dexamethasone, and isepamicin until postoperative 48 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Local infusion analgesia
Number of subjects: 40
Study: 22471452

Group type: EXPERIMENTAL
Intervention: Intervention group (n=474 smokers, mean age=44.56 years, SD=9.66 years)
Number of subjects: 3304

Group type: COMPARATOR
Intervention: Control group (n=454 smokers, mean age=44.47 years, SD=10.30 years)
Number of subjects: 3304
Study: 19908338

Group type: EXPERIMENTAL
Intervention: MR Enteroclysis (MRE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: MR Follow-Through (MRFT)
Number of subjects: 108
Study: 16814292

Group type: COMPARATOR
Intervention: Regularly menstruating exercising control women
Number of subjects: 3

Group type: COMPARATOR
Intervention: Regularly menstruating normally active control women
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 3
Study: 12732859

Group type: EXPERIMENTAL
Intervention: Closed suction (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open suction (OS)
Number of subjects: 0
Study: 10902994

Group type: EXPERIMENTAL
Intervention: 12 mg iron + either 1171 or 209 kJ
Number of subjects: 36

Group type: COMPARATOR
Intervention: 104 kJ + 0 iron
Number of subjects: 36
Study: 8881899

Group type: EXPERIMENTAL
Intervention: Cyclosporin 5 mg/kg per day decreasing to 3 mg/kg per day (Group A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cyclosporin 3 mg/kg per day increasing to 5 mg/kg per day (Group B)
Number of subjects: 78
Study: 1328784

Group type: EXPERIMENTAL
Intervention: 5000 I.U. heparin administered twice daily
Number of subjects: 594

Group type: COMPARATOR
Intervention: Low molecular weight heparin (3000 I.U. anti-Xa) administered daily
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Both groups (heparin and low molecular weight heparin)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Excluded group (patients with contraindications)
Number of subjects: 594
Study: 3904393

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3305116

Group type: EXPERIMENTAL
Intervention: Pancreatic enzymes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no pancreatic enzymes)
Number of subjects: 15
Study: 30454051

Group type: EXPERIMENTAL
Intervention: Multi-component community-based rehabilitation programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0